Triple negative breast cancer accounts for 15% of cases but causes a disproportionate number of deaths. Learn about symptoms ...

By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

It would be short-sided, erroneous and dangerous to think ill of mifepristone, which has several important applications,, M.D ...

Breast cancer is the second leading malignant disease in females worldwide. Over decades of research, breast cancer classification by molecular subtypes has ...

As genetic and biomarker tests become more common, so do new therapies that target specific tumor types and may lead to better outcomes ...

We know that most endometrial cancer cells have estrogen and/or progesterone receptors on their surfaces. Somehow, interaction of these receptors and these hormones leads to increased growth of the ...

Progesterone is involved in regulating the female menstrual cycle. Hormone receptor-positive breast cancer is fueled by estrogen and progesterone, while triple-negative breast cancer cells are not ...

Triple-positive breast cancer is a type of breast cancer that tests positive for estrogen receptors, progesterone receptors, and high levels of HER2 protein. Some types of breast cancer cells use ...

Development of a highly sensitive in vitro system to detect and discriminate between vitamin D receptor agonists and antagonists based on split-luciferase technique.

(OTCQB: CYDY) are on a tear as the biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced encouraging survival outcomes among ...